One significant area of research involves the use of advanced genetic testing to diagnose non-congenital adrenal hyperplasia (non-CAH) primary adrenal insufficiency (PAI). A study highlighted the ...

"Today's approval provides an important advance for patients with classic congenital adrenal hyperplasia ... The drug's label also warns of acute adrenal insufficiency or adrenal crisis, which ...

Neurocrine Biosciences, Inc.’s NBIX share price has dipped by 18.53%, which has investors questioning if this is right time ...

The FDA has granted priority review designation for two new drug applications for a selective corticotropin-releasing factor type 1 receptor to treat congenital adrenal hyperplasia, according to a ...

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use alongside glucocorticoids in managing classic congenital adrenal hyperplasia (CAH ...